Followers

Thursday, October 20, 2011

Biogen MS trial data robust; shares jump

Biogen MS trial data robust; shares jump (Reuters) - Full data from a late-stage clinical trial of Biogen Idec Inc's experimental multiple sclerosis drug, BG-12, showed robust results across multiple measures and revealed no new safety concerns. The news sent the biotech company's shares ... Biogen MS trial data robust; shares jump

No comments:

Post a Comment

Popular Posts